MiMedx Group Inc (OQ:MDXG)

Business Focus: Bio Medical Devices

Get the company report for the most recent outlook updated daily

Apr 30, 2024 04:01 pm ET

MIMEDX Announces First Quarter 2024 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2024. Recent Operating and Financial Highlights: First quarter 2024 net sales of $85 million, reflecting 18%...

Apr 16, 2024 08:00 am ET

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior...

Mar 27, 2024 08:00 am ET

MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a determination letter in connection with the RFD process related to AXIOFILL, a human-derived particulate...

Mar 20, 2024 07:00 am ET

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable...

Mar 13, 2024 08:00 am ET

MIMEDX Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of MIMEDX Connect™, an online product ordering and account management portal available to its customers through the Company’s website. “In our ongoing...

Mar 04, 2024 08:00 am ET

MIMEDX Announces Appointment of Two New Independent Directors

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant...

Feb 28, 2024 04:01 pm ET

MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2023. Recent Operating and Financial Highlights: Fourth quarter and full year 2023 net sales of...

Feb 20, 2024 08:00 am ET

MIMEDX to Present at TD Cowen 44th Annual Health Care Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference. TD Cowen | Boston, MA | March 4-6, 2024Presentation: Monday, March 4, 2024 at...

Feb 12, 2024 08:00 am ET

MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28,...

Jan 30, 2024 06:35 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 26, 2024 12:22 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...

Jan 25, 2024 07:44 pm ET

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation – MDXG

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially...

Jan 22, 2024 06:50 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 22, 2024 08:00 am ET

MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has enhanced its capital structure by refinancing its existing indebtedness and obtaining additional borrowing capacity in support of the Company’s future growth...

Jan 20, 2024 10:04 am ET

MDXG LOSS ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation – MDXG

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially...

Jan 19, 2024 08:30 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG

NEW YORK, Jan. 19, 2024 /PRNewswire/ --

Jan 18, 2024 05:06 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

Jan 17, 2024 11:04 am ET

MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG

Jan 17, 2024 10:25 am ET

MiMedx Group Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Block & Leviton is investigating MiMedx Group, Inc. (NASDAQ: MDXG) for potential securities law violations. Investors who have lost money in their MiMedx Group, Inc. investment should contact the firm to learn more about how they might recover...

Jan 15, 2024 11:30 pm ET

MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of MiMedx stockholders. Our investigation concerns...

Jan 14, 2024 10:45 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 12, 2024 04:00 pm ET

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ:

Jan 12, 2024 01:24 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) investors concerning the Company’s possible violations of federal securities laws.

Jan 11, 2024 12:54 pm ET

The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ:

Jan 06, 2024 10:30 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 02, 2024 05:11 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

Dec 29, 2023 05:00 pm ET

MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin. AXIOFILL Update...

Dec 28, 2023 08:00 am ET

MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued dividends, were automatically converted into...

Nov 13, 2023 08:00 am ET

MIMEDX to Participate in Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum Capital Group 14th Annual Alpha Select Conference Thursday,...

Nov 02, 2023 08:00 am ET

MIMEDX to Highlight Published Data at SAWC Fall

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV. In addition,...

Oct 30, 2023 04:01 pm ET

MIMEDX Announces Third Quarter 2023 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the quarter ended September 30, 2023. Recent Operating and Financial Highlights: Third quarter 2023 net sales of $81.7 million, an...

Oct 16, 2023 08:00 am ET

MIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2023 after the market close on Monday, October 30, 2023. The MIMEDX...

Sep 26, 2023 08:00 am ET

MIMEDX Announces Launch of EPIEFFECT™

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company’s core AWC offering for clinicians treating...

Sep 05, 2023 08:00 am ET

MIMEDX to Present at Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the following investor conferences: H.C. Wainwright 25th Annual Global Investment ConferencePresentation: Tuesday, September...

Aug 15, 2023 04:01 pm ET

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a research collaboration agreement with MIMEDX Group, Inc (Nasdaq:...

Aug 01, 2023 04:01 pm ET

MIMEDX Announces Second Quarter 2023 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2023, which ended June 30, 2023, including net sales of $81.3 million, net income of $1.2 million and Adjusted...

Jul 26, 2023 01:30 pm ET

Northland Capital Markets Institutional Investor Conference

MINNEAPOLIS, MN / ACCESSWIRE / July 26, 2023 / We are pleased to be hosting the Northland Capital Markets Institutional Investor Conference 2023 on Tuesday September 19, 2023, at the Minneapolis Marriott City Center, Downtown Minneapolis. We have over 90 companies to participating. The format will be 10 one-on-one meetings (or small group) scheduled in 35 minute increments.

Jul 18, 2023 08:00 am ET

MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1, 2023. The MIMEDX senior...

Jul 11, 2023 08:30 am ET

MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the Eleventh Circuit Court of Appeals affirmed the dismissal of the putative securities class action lawsuit brought against the Company and others in 2019. In the...

Jul 05, 2023 08:00 am ET

MIMEDX Appoints Doug Rice as Chief Financial Officer

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has appointed Doug Rice as the Company’s Chief Financial Officer, effective today. Pete Carlson, who has served in that role since March 2020, has resigned as...

Jun 20, 2023 04:01 pm ET

MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a strategic realignment designed to focus the Company’s resources on accelerating growth of its Wound & Surgical business, driving profitability and enhancing cash flow...

May 02, 2023 04:01 pm ET

MIMEDX Announces First Quarter 2023 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced operating and financial results for the first quarter 2023, which ended March 31, 2023, including net sales of $71.7...

Apr 18, 2023 08:00 am ET

MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on...

Mar 23, 2023 04:01 pm ET

MIMEDX Announces Chief Financial Officer Transition

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company...

Mar 16, 2023 08:00 am ET

MIMEDX Comments on Recent Data Brief Published by Office of Inspector General

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today applauded the recent report published by OIG entitled, “Some Skin Substitute Manufacturers Did Not Comply with New ASP Reporting...

Feb 28, 2023 04:01 pm ET

MIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced operating and financial results for the fourth quarter and full year 2022. Joseph H. Capper, MIMEDX Chief Executive Officer...

Feb 15, 2023 08:00 am ET

MIMEDX to Host Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call on February 28

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the fourth quarter and full year ended December 31, 2022 after the...

Jan 30, 2023 08:00 am ET

MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that its Board of Directors has appointed Joseph H. Capper as the Company’s Chief Executive Officer and a director of the...

Jan 09, 2023 08:02 am ET

MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today provided the following updates about its business. Reaffirms Fourth Quarter and Full Year 2022 ExpectationsThe Company announced that...

Jan 04, 2023 04:01 pm ET

MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED (“Gunze Medical”), a subsidiary of...

Jan 03, 2023 08:00 am ET

MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s...

Dec 08, 2022 08:00 am ET

MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform,...

Nov 10, 2022 08:00 am ET

MIMEDX to Present at Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the following investor conferences: Canaccord Genuity MedTech, Diagnostics and...

Nov 02, 2022 04:15 pm ET

MIMEDX Announces Third Quarter 2022 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced operating and financial results for the third quarter 2022, which ended September 30, 2022. Todd Newton, MIMEDX interim...

Oct 19, 2022 08:00 am ET

MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the third quarter ended September 30, 2022, after the market...

Oct 04, 2022 08:00 am ET

MIMEDX Appoints Matt Notarianni as Head of Investor Relations

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX...

Sep 20, 2022 08:00 am ET

MIMEDX Announces Launch of AXIOFILL™

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the launch of AXIOFILL™, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue. AXIOFILL...

Sep 19, 2022 07:00 am ET

MIMEDX Announces Launch of AMNIOEFFECT™

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate,...

Sep 12, 2022 04:30 pm ET

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that the Japanese Ministry of Health, Labour and Welfare (JMHLW) approved reimbursement of EPIFIX® to treat refractory or...

Sep 06, 2022 07:00 am ET

MIMEDX Announces Leadership Transition

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO)....

Aug 26, 2022 09:00 am ET

Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today recognized Board Member, Cato T. Laurencin, M.D., Ph.D. for his leadership and contributions to advance the field of regenerative...

Aug 04, 2022 04:07 pm ET

MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on Wednesday, August...

Aug 02, 2022 04:05 pm ET

MIMEDX Announces Second Quarter 2022 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced operating and financial results for the second quarter 2022, which ended June 30, 2022. Timothy R. Wright, MIMEDX...

Jul 27, 2022 08:00 am ET

MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the formation of a Regenerative Medicine Scientific Advisory Board (RMSAB) to provide guidance on the Company’s...

Jul 20, 2022 08:00 am ET

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on...

Jul 18, 2022 09:35 am ET

MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today. Ms. Surdez comes to MIMEDX with...

Jun 15, 2022 08:30 am ET

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced a collaboration agreement with Nordic Bioscience Clinical Development A/S (NBCD), a world-class Contract Research...

Jun 14, 2022 05:16 pm ET

Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change

Notes that a Majority of the Non-Affiliated, Non-Institutional Shares Voted Against the Re-Election of Incumbent Directors, and Against Approval of Executive Compensation

Jun 07, 2022 04:05 pm ET

MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that, based on the preliminary vote count provided by its proxy solicitor, shareholders have approved all proposals set...

Jun 07, 2022 02:42 pm ET

Prescience Point Capital Management Calls On MiMedx Group to Immediately Release Preliminary Voting Results of its Annual Meeting

Believes That a Massive Number of Shares Voted Against the Re-Election of Incumbent Directors and Against Approval of Executive Compensation

Jun 03, 2022 08:00 am ET

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today reminded shareholders to pre-register for the upcoming 2022 Annual Meeting of Shareholders, by no later than 9:00 a.m. Eastern Time...

Jun 02, 2022 08:03 am ET

MIMEDX Addresses Presentation by Prescience Point

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today addressed the highly misleading presentation published by Prescience Point on May 31, 2022, which mischaracterizes important facts...

May 31, 2022 04:05 pm ET

MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, mailed a letter to shareholders from Board Chair Dr. M. Kathleen Behrens in connection with its 2022 Annual Meeting of Shareholders...

May 31, 2022 02:05 pm ET

Prescience Point Capital Management Releases Presentation Detailing Board And Management Failures at MiMedx Group

Votes WITHHOLD against board directors Phyllis Gardner and James Bierman at 2022 Annual Meeting to send a message to MiMedx

May 31, 2022 08:00 am ET

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced receiving a $4.6 Million award to evaluate PURION® processed Dehydrated Human Amnion Chorion Membrane (DHACM) as an...

May 25, 2022 05:26 pm ET

Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that shareholders vote “FOR ALL” of the Company’s proposals including “FOR”...

May 20, 2022 09:00 am ET

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company’s Proposals

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”) today announced that leading proxy advisory firm Glass Lewis & Co (“Glass Lewis”) has recommended that shareholders vote “FOR ALL” of the Company’s proposals including “FOR” both of...

May 18, 2022 04:18 pm ET

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its 2022 Annual Meeting of...

May 18, 2022 08:55 am ET

Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received Letters of Serious Concern from other Shareholders

Disappointed that the MiMedx Board Has Resorted to Disinformation and Distortions to Distract Shareholders from the Board's and Management's Own Failures

May 16, 2022 08:00 am ET

MIMEDX Mails Letter to Shareholders

MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, has mailed a letter to shareholders in connection with its 2022 Annual Meeting of Shareholders scheduled for Tuesday, June 7, 2022 at...

May 09, 2022 08:00 am ET

MIMEDX Comments on Prescience Point’s False and Misleading Statements

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today commented on Prescience Point Capital Management’s (“Prescience Point”) highly misleading press release on May 6, 2022. MIMEDX...

May 06, 2022 09:12 am ET

Prescience Point Capital Management Issues Open Letter to Shareholders of MiMedx Group

Intends on Withholding Votes Against Directors Phyllis Gardner and James Bierman at 2022 Annual Meeting and Vote Against Approval of Executive Compensation

May 05, 2022 08:00 am ET

MIMEDX to Participate at Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will participate in the following investor conferences: Bank of America Securities 2022...

May 03, 2022 04:31 pm ET

MIMEDX Announces First Quarter 2022 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the filing of its first quarter 2022 Form 10-Q for the period ended March 31, 2022. Timothy R. Wright, MIMEDX Chief...

Apr 29, 2022 09:09 am ET

MIMEDX Comments on Prescience Point’s Recent Filing

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today issued the following statement in response to the filing of a Schedule 13D with the Securities and Exchange Commission by...

Apr 20, 2022 08:00 am ET

MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after the market close on...

Apr 05, 2022 08:00 am ET

MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced it will sponsor a lunch symposium at the Symposium on Advanced Wound Care (SAWC) Spring on April 6-10 in Phoenix,...

Mar 16, 2022 08:05 am ET

WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers Nationwide

TAMPA, Fla., March 16, 2022 /PRNewswire/ -- Leading wound care management and clinical services provider, WoundGenex, today announced a strategic partnership with MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX"), a transformational placental biologics company, to launch an exclusive version of WoundGenex's Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.

Mar 15, 2022 08:00 am ET

MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the...

Feb 28, 2022 04:06 pm ET

MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the filing of its 2021 Annual Report on Form 10-K for the year ended December 31, 2021. Timothy R. Wright, MIMEDX Chief...

Feb 16, 2022 08:35 am ET

Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the publication of a peer-reviewed study in the Journal of Wound Care evaluating the cost-effectiveness of the Company’s...

Feb 14, 2022 08:00 am ET

MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close...

Jan 28, 2022 12:40 pm ET

MIMEDX Announces Dismissal of Putative Securities Class Action Lawsuit

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that a federal court in Georgia has denied a motion to reconsider the dismissal of Carpenters Pension Fund of Illinois’...

Jan 10, 2022 08:00 am ET

MIMEDX Outlines Key Strategic Milestones for 2022

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), a transformational placental biologics company, today provided a recap of key 2021 accomplishments and outlined strategic milestones planned for 2022. The Company expects strong,...

Jan 04, 2022 04:05 pm ET

MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D.,...

Dec 22, 2021 08:00 am ET

MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 07, 2021 07:00 am ET

MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), a transformational placental biologics company, will provide new details about near- and long-term growth opportunities for its multimodal placental tissue platform at today’s virtual...

Nov 30, 2021 08:00 am ET

MIMEDX Announces Speakers for December 7 Investor Day

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the speakers for its upcoming virtual Investor Day that will be held on Tuesday,...

Nov 22, 2021 08:00 am ET

MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief...

Nov 17, 2021 08:00 am ET

Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM) Outperforms Standard of Care in Select Mohs Defect Reconstructions

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced publication of a peer-reviewed study in Facial Plastic Surgery & Aesthetic...

Nov 02, 2021 04:50 pm ET

MIMEDX Announces Third Quarter 2021 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the filing of its third quarter 2021 Form 10-Q for the period ended...

Nov 02, 2021 08:00 am ET

MIMEDX to Participate at Upcoming Investor Conferences

Nov 01, 2021 08:30 am ET

Two New Studies Demonstrate in vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinop

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion...

Oct 20, 2021 08:00 am ET

MIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the third quarter ended...

Oct 14, 2021 04:05 pm ET

MIMEDX to Host Virtual Investor Day on December 7, 2021

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning...

Oct 13, 2021 07:00 am ET

Net Health Agreement with MIMEDX Streamlines Complex Insurance Benefits Verifications

PITTSBURGH, Oct. 13, 2021 /PRNewswire/ -- Net Health, a leading provider of analytics and cloud-based software for specialty medical providers, announced today that it has added MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX") to the list of leading wound care providers that rely on Net Health® Wound Care's in-chart ordering platform, CTP Connections. Through the agreement, hospital and outpatient wound care providers can quickly and efficiently submit electronic insurance verification forms and secure approvals for MIMEDX tissue-based products.

Sep 13, 2021 06:30 am ET

MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced top-line results from two late-stage musculoskeletal clinical trials of the...

Sep 08, 2021 07:30 am ET

MIMEDX Announces Effectiveness of Shelf Registration Statement

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 on file with the Securities and...

Sep 07, 2021 08:00 am ET

MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 27, 2021 09:00 am ET

MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the filing of a shelf registration statement on Form S-3 with the Securities and...

Aug 17, 2021 08:30 am ET

Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced publication of its peer-reviewed study in the Journal of Wound Care (JWC),...

Aug 12, 2021 08:30 am ET

MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the promotion of Marion Snyder to Chief of Staff, Senior Vice President,...

Aug 03, 2021 05:22 pm ET

MIMEDX Announces Second Quarter 2021 Operating and Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the filing of its second quarter 2021 Form 10-Q for the period ended June 30,...

Jul 20, 2021 08:00 am ET

MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4

Jul 14, 2021 09:00 am ET

NAACP to Present Historic Spingarn Medal to Regenerative Engineering Pioneer Cato T. Laurencin, M.D., Ph.D., at 112th Annual Convention

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today congratulates Cato T. Laurencin, M.D., Ph.D., Van Dusen Distinguished Endowed Professor at...

Jun 28, 2021 08:00 am ET

MIMEDX Joins Russell 3000® and 2000® Indexes

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today confirmed that FTSE Russell will add the Company’s common stock to its broad-market...

Jun 16, 2021 08:00 am ET

MIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference

Jun 15, 2021 04:54 pm ET

New Study Demonstrates Potential for MIMEDX Purion® Processed Dehydrated Human Amnion/Chorion Membrane to Modulate Pathological Scar Tissue Formation

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced publication of its peer-reviewed study in the Journal of Investigative...

Jun 08, 2021 08:30 am ET

MIMEDX Receives Regulatory Approval to Commercialize EPIFIX® in Japan

MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced successful regulatory approval by the Japanese Ministry of Health, Labour and...

May 27, 2021 08:00 am ET

MIMEDX to Participate at the Jefferies Virtual Healthcare Conference

MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief...

May 25, 2021 08:30 am ET

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today reminded shareholders to pre-register for the upcoming 2021 Annual Meeting of Shareholders...

May 12, 2021 08:00 am ET

MIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today reminded shareholders to vote at the upcoming 2021 Annual Meeting of Shareholders (“Annual...

May 10, 2021 08:00 am ET

MIMEDX to Participate at Upcoming Investor Conferences

May 06, 2021 08:00 am ET

MIMEDX Announces Collaborative Agreement with the Wake Forest Institute for Regenerative Medicine

MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced a collaborative agreement with the Wake Forest Institute for Regenerative...

May 04, 2021 09:15 am ET

MIMEDX Urges Shareholders to Consider Prescience Point’s Motivations Before Voting Their Shares at the Company’s Annual Meeting

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today urged shareholders to consider several key questions about Prescience Point’s interests,...

May 03, 2021 08:02 am ET

MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it has filed definitive proxy materials with the U.S. Securities and...

Apr 28, 2021 05:00 pm ET

MiMedx Announces First Quarter 2021 Financial and Operating Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the filing of its first quarter 2021 Form 10-Q for the period ended March 31,...

Apr 28, 2021 10:21 am ET

MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the addition of Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance...

Apr 22, 2021 08:00 am ET

MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the first quarter ended March 31, 2021...

Apr 19, 2021 09:00 am ET

MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that the last patients have completed their last clinical visits in two...

Apr 16, 2021 12:06 pm ET

MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management

MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management (“Prescience Point”) submitted a notice of...

Mar 30, 2021 08:00 am ET

MiMedx Awarded Amniotic Tissue Supplier Agreement with Premier® Inc.’s SURPASS™ Purchasing Program

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced that the Company has been awarded a Group Purchasing Agreement for its amniotic...

Mar 08, 2021 05:33 pm ET

MiMedx Announces Appointment of Phyllis Gardner, M.D. to Board of Directors

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced the appointment of Phyllis Gardner, M.D. to its Board of Directors. Regarded for...

Mar 08, 2021 05:32 pm ET

MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced the filing of its 2020 Annual Report on Form 10-K for the period ended December 31,...

Mar 03, 2021 08:00 am ET

MiMedx to Participate at Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor conferences: H.C....

Mar 02, 2021 08:00 am ET

MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the fourth quarter and full year ended December...

Feb 26, 2021 03:00 am ET

SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm

National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Infinity Q Diversified Alpha Fund, JELD-WEN Holding, Inc., and MiMedx Group, Inc. If you are a current owner of shares of any...

Feb 10, 2021 08:00 am ET

MiMedx to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial...

Jan 06, 2021 08:00 am ET

Reminder: MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference

Jan 04, 2021 08:00 am ET

MiMedx to Participate at the H.C. Wainwright BioConnect 2021 Conference

Dec 16, 2020 08:14 am ET

Prescience Point Capital Management Raises Price Target on MiMedx Group to $31 Per Share

BATON ROUGE, La., Dec. 16, 2020 /PRNewswire/ -- Prescience Point Capital Management, a research-focused, catalyst-driven investment firm, today announced it has issued new research on MiMedx Group Inc. (Nasdaq: MDXG), raising the price target on the leading advanced wound care and therapeutic biologics company to $31 per share. Prescience Point is one of the company's largest shareholders, owning 9 million or approximately 6.5% of the fully-diluted common stock of MiMedx.

Dec 07, 2020 08:00 am ET

MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on...

Dec 01, 2020 09:21 am ET

MiMedx Appoints Jack Howarth as Senior Vice President, Investor Relations

MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced the appointment of Jack Howarth as Senior Vice President of Investor Relations. Mr....

Nov 24, 2020 05:15 pm ET

MiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 13, 2020 08:00 am ET

MiMedx To Host Virtual 2020 Annual Meeting of Shareholders on Friday, November 20

MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided additional information about its upcoming virtual 2020 Annual Meeting of Shareholders...

Nov 12, 2020 08:00 am ET

MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief...

Nov 04, 2020 04:06 pm ET

MiMedx Announces Third Quarter 2020 Financial Results

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced the filing of its third quarter 2020 Form 10-Q for the period ended September 30, 2020....

Nov 04, 2020 08:00 am ET

MiMedx To Advance the Conversation of Study Bias in the Clinical Evaluation of Skin Substitutes in Chronic Wounds at SAWC FALL

MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, announced it will sponsor an Innovation Theater at the Symposium on Advanced Wound Care Fall (SAWC Fall)...

Nov 03, 2020 05:30 pm ET

MiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today confirmed that the Company’s common stock will commence trading on The Nasdaq Stock Market at the...

Nov 03, 2020 08:00 am ET

MiMedx Announces Largest U.S. Commercial Payor Will Provide Coverage for EpiFix in the Treatment of Diabetic Foot Ulcers

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that the largest U.S. Commercial payor will now provide coverage for EpiFix®, the...

Oct 30, 2020 04:52 pm ET

MiMedx Announces Relisting on Nasdaq

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that The Nasdaq Stock Market LLC has approved MiMedx’s application for the relisting of...

Oct 29, 2020 04:05 pm ET

MiMedx to Host Third Quarter 2020 Financial Results Call on November 5

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the third quarter ended September 30, 2020...

Oct 15, 2020 08:23 am ET

MiMedx Files Definitive Proxy Materials

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange...

Sep 24, 2020 07:05 am ET

Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the appointment of John M. Gay to serve as the Company’s Chief Financial Officer and the appointment of James L. Bierman to its Board of Directors. Mr. Gay is an accomplished...

Sep 21, 2020 08:30 am ET

MiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, announced the conclusion of enrollment into its Phase 2B study of its micronized injectable amniotic...

Sep 21, 2020 06:15 am ET

MiMedx Announces Preliminary Third Quarter 2020 Net Sales

MiMedx Group, Inc., (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided guidance regarding certain unaudited, preliminary third quarter financial results. Net...

Sep 17, 2020 11:00 am ET

MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the conclusion of enrollment for a Phase 3 study of plantar fasciitis, an...

Sep 14, 2020 08:00 am ET

MiMedx Launches EpiCord Expandable Placental Allograft as Addition to Market Leading Portfolio

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the launch of EpiCord Expandable, the latest advancement in its portfolio of...

Aug 24, 2020 09:00 am ET

MiMedx to Discuss Strategic Priorities at Upcoming Virtual 2019 Annual Meeting of Shareholders

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today provided additional information about its upcoming virtual 2019 Annual Meeting of...

Aug 10, 2020 09:00 am ET

MiMedx Welcomes Robert B. Stein, M.D., Ph.D., to Head Revitalized R&D Efforts

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Robert B. Stein, M.D., Ph.D., as Executive Vice President,...

Aug 04, 2020 05:21 pm ET

MiMedx Files Second Quarter 2020 Form 10-Q

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its second quarter 2020 Form 10-Q for the period ended June 30,...

Aug 03, 2020 08:06 am ET

MiMedx Files Definitive Proxy Materials

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and...

Jul 28, 2020 07:30 am ET

MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Rohit Kashyap, Ph.D., as Executive Vice President and Chief...

Jul 06, 2020 06:45 am ET

MiMedx Announces Filing of 2020 First Quarter Form 10-Q

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2020 first quarter Form 10-Q. The Company has additionally...

Jul 06, 2020 06:00 am ET

MiMedx Announces Filing of 2019 Annual Report

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2019 Annual Report. With this filing, we are one step closer...

Jul 02, 2020 09:00 am ET

MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings,...

May 08, 2020 07:26 pm ET

MiMedx Provides Update on Payment Protection Program Loan

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it is repaying the Payment Protection Program (PPP) Loan received through...

May 05, 2020 04:30 pm ET

MiMedx Announces Appointment of William L. Phelan as Chief Accounting Officer

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the appointment of William L. Phelan as Senior Vice President and Chief...

Apr 21, 2020 10:18 am ET

MiMedx Announces Additional Access to Capital and Financing

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has received notice from Bank of America that its application for a...

Apr 06, 2020 12:27 pm ET

MiMedx Announces Settlement of VA Pricing Investigation

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Department of Justice (the “DOJ”),...

Mar 19, 2020 06:06 am ET

MiMedx Names Peter M. Carlson as Chief Financial Officer

MARIETTA, Ga., March 19, 2020 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Peter M. Carlson, Executive Vice President of Finance, has been named as the Company's Chief Financial Officer, effective immediately.

Mar 17, 2020 05:43 pm ET

MiMedx Announces Filing of 2018 Annual Report

MARIETTA, Ga., March 17, 2020 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2018 Annual Report, which includes the Company's audited consolidated statements of operations, and stockholders' equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.

Sep 20, 2019 04:15 pm ET

MiMedx Announces Resignation of Board Member

MARIETTA, Ga., Sept. 20, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Luis A. Aguilar has notified the Company of his resignation from the Board of Directors. The Board expresses its appreciation for his service.

Aug 08, 2019 05:32 pm ET

MiMedx Announces Agreement Regarding 2019 and 2020 Shareholder Meetings

MARIETTA, Ga., Aug. 8, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced an agreement with the plaintiff (the "Plaintiff") in the matter City of Hialeah Employees' Retirement System v. MiMedx Group, Inc. As has been previously reported, MiMedx is working diligently to complete its audited financial statements (the "Restatement"). The agreement provides that MiMedx will work in good faith to endeavor to complete the Restatement by December 16, 2019. The

May 23, 2019 04:45 pm ET

MiMedx Announces Conclusion of Audit Committee's Independent Investigation

MARIETTA, Ga., May 23, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Audit Committee of the Board of Directors has concluded its independent investigation ("the Investigation") into matters relating to, among other things, allegations regarding certain sales and distribution practices at the Company.

May 09, 2019 08:00 am ET

MiMedx Appoints Timothy R. Wright as Chief Executive Officer

MARIETTA, Ga., May 9, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that its Board of Directors has appointed Timothy R. Wright as Chief Executive Officer, effective May 13, 2019. Mr. Wright succeeds David Coles, who has served as Interim Chief Executive Officer since July 2018.

May 07, 2019 11:55 am ET

Prescience Point Nominates Slate of Highly-Qualified Director Candidates for Election to MiMedx Board

BATON ROUGE, La., May 7, 2019 /PRNewswire/ -- Prescience Point Capital Management, LLC, a private investment management firm, together with certain investment partnerships under its management (collectively, "Prescience Point"), today announced that it has nominated a slate of four world-class candidates for election to the MiMedx Group, Inc. ("MiMedx" or the "Company") (Ticker: MDXG) Board of Directors (the "Board") at the Company's upcoming Annual Meeting of Shareholders (the "Annual Meeting"), scheduled to be held on June 17, 2019. Prescience Point, together with its director nominees, ow

Apr 11, 2019 04:32 pm ET

MiMedx Announces Board Approval of Long-Range Strategic Plan

MARIETTA, Ga., April 11, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today reinforced its priorities for 2019 as part of its long-range strategic plan to enhance value for all MiMedx stakeholders. These priorities include sharpening our focus on the advanced wound care segment, developing and expanding our portfolio pipeline, and driving continued operational excellence to support future growth and sustained productivity.

Jan 08, 2019 08:20 am ET

Prescience Point Capital Management Issues Positive Report on MiMedx Group Inc. (OTC: MDXG)

BATON ROUGE, La., Jan. 8, 2019 /PRNewswire/ --

Dec 05, 2018 07:05 am ET

MiMedx Announces Resignation Of Outside Auditor

MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that on December 4, 2018, Ernst & Young LLP informed the Company's Audit Committee that it has resigned from the engagement to audit the Company's financial statements for the years ended December 31, 2017 and 2018, effective immediately. Additional information about Ernst & Young LLP's resignation will be included in a Form 8-K to be filed with the SEC no later than December 11, 2018.

Dec 05, 2018 07:02 am ET

MiMedx Announces Leadership Changes And Promotions

MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced certain leadership changes and promotions in conjunction with its plans to implement a broad-based organizational realignment program designed to position the business for long-term success. Additional details regarding the program are available in the Company's press release issued earlier today.

Dec 05, 2018 07:00 am ET

MiMedx Announces Organizational Realignment Program

MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its plans to implement a broad-based organizational realignment, cost reduction and efficiency program to better ensure the Company's cost structure is appropriate given its revenue expectations. MiMedx plans to execute these initiatives while continuing to deliver products and support for healthcare providers and the patients they serve.

Nov 07, 2018 04:57 pm ET

Jack Henry & Associates Set to Join S&P 500; EQT, Equitrans Midstream, MasTec to Join S&P MidCap 400; Superior Energy Services, United Natural Foods to Join S&P SmallCap 600

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:

Nov 07, 2018 07:02 am ET

MiMedx Adopts Limited Duration Shareholder Rights Plan In Response To Delisting From Nasdaq

MARIETTA, Ga., Nov. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that its Board of Directors has unanimously authorized the adoption of a limited duration shareholder rights plan (the "Rights Plan") following receipt of notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that Nasdaq will suspend trading in the Company's stock effective at the open of business on Thursday, November 8, 2018.

Nov 07, 2018 07:00 am ET

MiMedx Receives Nasdaq Delisting Notification

MARIETTA, Ga., Nov. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the interim progress report submitted by the Company on October 31, 2018, the Nasdaq Hearings Panel (the "Panel") has reconsidered the Company's request for continued listing of the Company's common stock on The Nasdaq Capital Market and has determined that Nasdaq will suspend trading in the Company's stock effectiv

Nov 06, 2018 11:29 am ET

MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference

MARIETTA, Ga., Nov. 6, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts reporting on the Company's EpiFix® dehydrated Human Amnion/Chorion Membrane (dHACM) allograft and EpiCord® dehydrated human umbilical cord (dHUC) allograft will be presented at the Desert Foot 15th Annual Multi-Disciplinary Limb Salvage Conference in Phoenix, Arizona. The conference begins Wednesday, November 7, 2018, and concludes on Saturday, November 10, 2018.

Oct 31, 2018 01:26 pm ET

MiMedx to Present Clinical and Scientific Studies at SAWC Fall Meeting

MARIETTA, Ga., Oct. 31, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts highlighting studies on the Company's EpiFix® dehydrated Human Amnion/Chorion Membrane (dHACM) allograft and EpiCord® dehydrated human umbilical cord (dHUC) allograft will be presented at the 2018 Symposium on Advanced Wound Care Fall (SAWC Fall) at Caesars Palace in Las Vegas, Nevada. The SAWC, now in its 31st year, is the official meeting for members of The Association for the Advancement of Wo

Sep 25, 2018 08:30 am ET

MiMedx Publishes Positive Results From Clinical Study Of Human Umbilical Cord For Diabetic Foot Ulcers

MARIETTA, Ga., Sept. 25, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a new clinical study has been published in the peer-reviewed International Wound Journal, which evaluated the safety and efficacy of using dehydrated human umbilical cord (dHUC - EpiCord) for chronic diabetic foot ulcers (DFUs).

Sep 20, 2018 05:15 pm ET

MiMedx Announces Nasdaq Listing Extension

MARIETTA, Ga., Sept. 20, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing of the Company's common stock on The Nasdaq Capital Market pursuant to an extension through February 25, 2019, subject to the condition that MiMedx regain compliance with its SEC reporting obligations and Nasdaq listing rules by February 25, 2019 and provide the Panel with certain interim progress reports. If the Company do

Sep 20, 2018 05:10 pm ET

Mimedx Provides Update on Previously Announced Senior Executive Separations

MARIETTA, Ga., Sept. 20, 2018 /PRNewswire/ -- The Board of Directors (the "Board") of MiMedx Group, Inc. (Nasdaq: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has determined that the previously announced separations of four senior MiMedx executives – Parker H. Petit, William C. Taylor, Michael J. Senken, and John E. Cranston (collectively, the "Separated Employees") – be treated as terminations "for cause". The Compensation Committee separately reached this determination as well. These determinations are based on information iden

Aug 24, 2018 08:30 am ET

MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®

MARIETTA, Ga., Aug. 24, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a new study regarding the use of EpiFix® in the treatment of diabetic foot ulcers (DFUs) has been published in the peer-reviewed journal, International Wound Journal.

Aug 15, 2018 05:15 pm ET

MiMedx Receives Additional Nasdaq Listing Notice Due to Late Form 10-Q

MARIETTA, Ga., Aug. 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (Nasdaq: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received written notification, as expected, from the Nasdaq Stock Market indicating that the Company's failure to timely file a Form 10-Q for the period ended June 30, 2018 could serve as an additional basis for delisting, and that the Company should be prepared to address the additional delinquency at its already scheduled hearing in September before a Nasdaq Hearings Panel (the "Panel"). Nasdaq previously notifie

Aug 15, 2018 01:30 pm ET

MiMedx Provides Additional Information and Context to Wall Street Journal Article

MARIETTA, Ga., Aug. 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today provided additional background and context to certain points, including third party statements, in an article published by The Wall Street Journal ("WSJ") on August 14, 2018:

Aug 13, 2018 08:00 am ET

MiMedx announces Nasdaq listing extension and Hearing Date

MARIETTA, Ga., Aug. 13, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a Nasdaq Hearings Panel (the "Panel") granted the Company's request for a listing extension. This allows for the continued trading of the Company's common stock on The Nasdaq Stock Market until the Panel make its determination of the Company's appeal of the Nasdaq staff's delisting notification.

Aug 09, 2018 10:00 am ET

MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia

MARIETTA, Ga., Aug. 9, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received regulatory approval from the Therapeutics Goods Administration (TGA) in Australia to market and sell a broad array of the Company's dehydrated Human Amnion/Chorion Membrane (dHACM) products. This includes EpiFix®, AmnioFix®, EpiBurn®, AmnioFix Injectable, and AmnioFix Wrap, among others.

Aug 02, 2018 08:30 am ET

MiMedx Announces Publication Of Phase 2B Clinical Trial Efficacy Data For Micronized dHACM In The Treatment Of Plantar Fasciitis In Foot & Ankle International

MARIETTA, Ga., Aug. 2, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that the positive pain and foot function results from its Phase 2B clinical trial of micronized dHACM (dehydrated Human Amnion/Chorion Membrane) in the treatment of Plantar Fasciitis have been published in the peer-reviewed journal, Foot & Ankle International. The publication of this data follows the Company's late-March announcement (3/26/18 Positive Pain and Foot Function Results) that it achieved the primary and seco

Aug 01, 2018 11:00 am ET

Schubert Jonckheer & Kolbe LLP Launches Investigation into Possible Breaches of Fiduciary Duty by MiMedx Group, Inc.'s Directors and Officers

SAN FRANCISCO, Aug. 1, 2018 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating whether certain directors and officers of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ:MDXG), a biopharmaceutical company, breached their fiduciary duties by causing the Company to engage in accounting manipulation and issue false and misleading statements to shareholders and the market.

Jul 26, 2018 05:00 pm ET

MiMedx Announces Receipt of Nasdaq Letter

MARIETTA, Ga., July 26, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today provided an update concerning the status of its compliance with the Listing Rules of the Nasdaq Stock Market.

Jul 18, 2018 04:30 pm ET

MiMedx Appoints Mark Graves Chief Compliance Officer To Strengthen Corporate Compliance Practices

MARIETTA, Ga., July 18, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has appointed Mark P. Graves to the position of Chief Compliance Officer. Mr. Graves will be responsible for providing direction and oversight of MiMedx's compliance program, including the Company's regulatory and legal compliance matters related to the Company's risk management, sales operations and financial reporting. Mr. Graves will report to Ed Borkowski, the Company's Executive Vice President and Interim Chi

Jul 10, 2018 06:11 am ET

Hynes Keller & Hernandez, LLC Announces Investigation of MiMedx Group, Inc. (MDXG)

NEW YORK, July 10, 2018 /PRNewswire/ -- Hynes Keller & Hernandez, LLC is investigating potential claims against certain officers and directors of MiMedx Group, Inc. (NASDAQ: MDXG). Our investigation focuses on whether MiMedx's officers and/or directors breached their fiduciary duties to MiMedx's shareholders or otherwise violated state or federal laws.

Ad blocking detected

MiMedx Group Inc (OQ:MDXG)

Business Focus: Bio Medical Devices